A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

NCT07483450 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis
Primary Progressive Multiple Sclerosis

Interventions

DRUG: Ocrelizumab

Sponsor

Hoffmann-La Roche